

## Sage Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022

February 10, 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 10, 2022-- Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on Thursday, February 24, 2022 at 8:00 a.m. ET to announce fourth quarter and full year 2021 financial results and discuss recent business updates.

The webcast can be accessed on the investor page of Sage's website at <u>investor.sagerx.com</u>. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.

## **About Sage Therapeutics**

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit <a href="https://www.sagerx.com">www.sagerx.com</a>.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220209005802/en/

## Investor Contact Helen Rubinstein

315-382-3979 <a href="mailto:helen.rubinstein@sagerx.com">helen.rubinstein@sagerx.com</a>

**Media Contact** 

Maureen L. Suda 617-949-4289 maureen.suda@sagerx.com

Source: Sage Therapeutics, Inc.